{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"IWG criteria was used to determine disease progression","groups":[{"description":"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.\n\nGRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.","id":"OG000","title":"Arm I (Nonmyeloablative Regimen)"},{"description":"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.\n\nGroup A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.\n\nGroup B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.\n\nTRANSPLANTATION: Patients undergo PBSC infusion on day 0.\n\nGRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.","id":"OG001","title":"Arm II (Myeloablative Regimen)"}],"paramType":"NUMBER","populationDescription":"2 patients in the nonmyeloablative arm did not receive a transplant due to relapse and withdrawal of consent","reportingStatus":"POSTED","timeFrame":"After stem cell infusion to date of last follow up.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"participants"}